53. Sjogren syndrome Clinical trials / Disease details
Clinical trials : 305 / Drugs : 325 - (DrugBank : 104) / Drug target genes : 58 - Drug target pathways : 188
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05383677 (ClinicalTrials.gov) | October 1, 2022 | 29/3/2022 | Anifrolumab Treatment for 24 Weeks in Patients With Primary Sjögren's Syndrome | ANIfrolumab Treatment for 24 Weeks in Patients With Primary Sjögren's Syndrome - Efficacy and Safety Assessment in a Randomized, Double-blind, Placebo-controlled Phase-IIa Proof-of-concept Trial (ANISE-II) | Sjogren's Syndrome | Drug: Anifrolumab;Drug: Placebo | University Medical Center Groningen | AstraZeneca | Recruiting | 18 Years | N/A | All | 30 | Phase 2 | Netherlands |